ASH 2022 | Nelarabine in combination with etoposide and cyclophosphamide in R/R T-ALL
Marlise Luskin
• 11 Dec 2022
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, comments on the potential role of nelarabine combination therapy in adolescent and young adult (AYA) patients with T-cell acute lymphoblastic leukemia (T-ALL). Patients who progress on first-line therapy have limited options, and combination approaches with nelarabine may result in superior outcomes relative to nelarabine monotherapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Research Funding; Pfizer: Honoraria; Novartis: Research Funding.
